Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Total Debt Growth (3y) (2013 - 2017)

Analysis

Exelixis (EXEL) Total Debt Growth (3y) (2013 - 2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 0.08%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 19.52%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 4.76%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -22.30%
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2017 11.57%
Dec 30, 2016 27.11%
Sep 30, 2016 5.60%
Jun 30, 2016 4.69%
Mar 31, 2016 4.40%
Dec 31, 2015 -5.65%
Sep 30, 2015 -5.74%
Jun 30, 2015 -6.17%
Mar 31, 2015 -5.14%
Dec 31, 2014 25.42%
Sep 30, 2014 13.68%
Jun 30, 2014 12.51%
Dec 31, 2013 -9.70%